ストックスクリーナーアプリを入手
24.99
0.73%
0.18
Zai Lab Limited Adr (ZLAB) 最新ニュース
Zai Lab Limited (9688.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zai Lab Limited To Present First Global Data From Clinical Trial Evaluating Zocilurtatug Pelitecan As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer - marketscreener.com
Zai Lab stock trades without a verified September catalyst - AD HOC NEWS
ZLAB - Finviz
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In T - Benzinga
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
Zai Lab LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
ZLAB Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Slip 2.76%Earnings Surprise Stocks - dars.gov.et
ZLAB Stock Price, Quote & News - Syfe
Zai Lab LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Former Zai Lab (NASDAQ: ZLAB) executive lines up multi-million ADS sale - Stock Titan
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)? - Yahoo Finance
Zai (ZLAB) EPS and Revenue: The Available Earnings Metric Delivers a Beat in Latest Trading; Market Response: Shares Finish 2.08% Down in the Available RecordEPS Miss Report - dars.gov.et
Zai (ZLAB) EPS and Revenue: The Available Earnings Metric Delivers a Beat in Latest Trading; Market Response: Shares Finish 2.08% Down in the Available RecordOne-Time Loss Impact - dars.gov.et
Zai Lab (NASDAQ: ZLAB) holder lines up Aug. 19 ADS sale after recent trades - Stock Titan
Zai Lab: Revenue Growth And Zoci's Upside Optionality (NASDAQ:ZLAB) - Seeking Alpha
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis - Business Wire
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis - Yahoo Finance
Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock - MarketBeat
William Lis Sells 8,506 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Is Zai Lab’s (ZLAB) Rising Losses for Pipeline Expansion Strengthening or Straining Its Investment Case? - Sahm
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Zai Lab CFO Chen Yajing Sells 619 ADS Shares via Rule 10b5-1 Trading Plan - Kalkine Media
Zai Lab (NASDAQ:ZLAB) Shares Gap DownWhat's Next? - MarketBeat
Zai Lab (ZLAB) insider William Lis plans sale of 8,506 ADS on NASDAQ - Stock Titan
ZLAB (NASDAQ: ZLAB) filer plans sale of 619 American Depositary Shares - Stock Titan
Zai Lab (ZLAB) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Zai Lab Limited (NASDAQ:ZLAB) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
ZLAB Q2 2026 Earnings: Narrower Loss Beats Consensus by 24%Earnings Turnaround - dars.gov.et
ZLAB Q2 2026 Earnings: Narrower Loss Beats Consensus by 24%Guidance vs Actual - dars.gov.et
ZLAB Q2 2026 Earnings: Narrower Loss Beats Consensus by 24%Basic EPS Analysis - dars.gov.et
CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB) - The Globe and Mail
Zai Lab (ZLAB) Stock Jumps As Revenue Holds But Losses Deepen - Sahm
Zai Lab Q2 Earnings Call Highlights - finance.yahoo.com
Zai Lab Q2 Earnings Call Highlights - sharewise.com
Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Form 8K ZAI LAB LIMITED For: 6 August By Investing.com - Investing.com Nigeria
Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings - MarketBeat
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings - Yahoo Finance
Zai Lab (NASDAQ: ZLAB) expands pipeline as Q2 2026 loss reaches $50.8M - Stock Titan
Zai Lab (NASDAQ: ZLAB) posts Q2 2026 net loss of $50.8M - Stock Titan
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates - Business Wire
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates - BioSpace
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Zai Lab’s zoci targets previously treated neuroendocrine cancers - Stock Titan
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) - Business Wire
Zai Lab (ZLAB) to Post Quarterly Earnings on Thursday - MarketBeat
UBS Keeps Their Buy Rating on Zai Lab Ltd (1ZLB) - The Globe and Mail
2.76%
0.02%
大文字化:
|
ボリューム (24 時間):